Prof. Kamal D. Moudgil

Professor

Email: [email protected]

1979 M.B.B.S., Panjabi University, Medicine

Publications (Selected)

1. Nanjaiah, H., & Moudgil, K. D. (2025). Pristimerin inhibits the progression of antibody-induced autoimmune arthritis. Scandinavian Journal of Rheumatology, 54(3), 198-203.
2. Nanjaiah, H., & Moudgil, K. D. (2024). Targeted Therapy of Antibody-Induced Autoimmune Arthritis Using Peptide-Guided Nanoparticles. International Journal of Molecular Sciences, 25(22), 12019.
3. Venkatesha, S. H., Durai, M., & Moudgil, K. D. (2024). Epitope spreading in autoimmune diseases. In Infection and autoimmunity (pp. 61-89). Academic press.
4. Moudgil, K. D., & Meka, R. R. (2023). U.S. Patent No. 11,766,403. Washington, DC: U.S. Patent and Trademark Office.
5. Nanjaiah, H., & Moudgil, K. D. (2023). The utility of peptide ligand-functionalized liposomes for subcutaneous drug delivery for arthritis therapy. International Journal of Molecular Sciences, 24(8), 6883.
6. Moudgil, K. D., & Venkatesha, S. H. (2022). The anti-inflammatory and immunomodulatory activities of natural products to control autoimmune inflammation. International journal of molecular sciences, 24(1), 95.
7. Langan, D., Perkins, D. J., Vogel, S. N., & Moudgil, K. D. (2021). Microbiota-derived metabolites, indole-3-aldehyde and indole-3-acetic acid, differentially modulate innate cytokines and stromal remodeling processes associated with autoimmune arthritis. International Journal of Molecular Sciences, 22(4), 2017.
8. Acharya, B., Meka, R. R., Venkatesha, S. H., Lees, J. R., Teesalu, T., & Moudgil, K. D. (2020). A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis. Molecular and cellular probes, 51, 101530.
9. Langan, D., Rose, N. R., & Moudgil, K. D. (2020). Common innate pathways to autoimmune disease. Clinical Immunology, 212, 108361.
10. Moudgil, K. D. (2020). Viewing autoimmune pathogenesis from the perspective of antigen processing and determinant hierarchy. Critical Reviews™ in Immunology, 40(4).
11. Meka, R. R., Venkatesha, S. H., Acharya, B., & Moudgil, K. D. (2019). Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy. Nanomedicine, 14(11), 1455-1469.
12. Langan, D., Kim, E. Y., & Moudgil, K. D. (2019). Modulation of autoimmune arthritis by environmental ‘hygiene’and commensal microbiota. Cellular immunology, 339, 59-67.
13. Venkatesha, S. H., & Moudgil, K. D. (2019). Celastrol suppresses experimental autoimmune encephalomyelitis via MAPK/SGK1-regulated mediators of autoimmune pathology. Inflammation Research, 68(4), 285-296.
14. Venkatesha, S. H., Dudics, S., Song, Y., Mahurkar, A., & Moudgil, K. D. (2018). The miRNA expression profile of experimental autoimmune encephalomyelitis reveals novel potential disease biomarkers. International journal of molecular sciences, 19(12), 3990.
15. Guo, W., Imai, S., Yang, J. L., Zou, S., Li, H., Xu, H., ... & Ren, K. (2018). NF-KappaB pathway is involved in bone marrow stromal cell-produced pain relief. Frontiers in Integrative Neuroscience, 12, 49.
16. Meka, R. R., Venkatesha, S. H., & Moudgil, K. D. (2018). Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis. Journal of Controlled Release, 286, 279-288.

Profile Details

https://www.medschool.umaryland.edu/profiles/moudgil-kamal/

https://scholar.google.com/citations?user=74WKkckAAAAJ&hl=en

https://www.researchgate.net/profile/Kamal-Moudgil